Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
The UK ortho and woundcare group might yet pounce on Nuvasive.
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…